Cargando…
The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland
Vaccine hesitancy is a major threat to the success of COVID-19 vaccination programs. The present cross-sectional online survey of adult Poles (n = 1020) expressing a willingness to receive the COVID-19 vaccine was conducted between February and March 2021 and aimed to assess (i) the general trust in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069794/ https://www.ncbi.nlm.nih.gov/pubmed/33919672 http://dx.doi.org/10.3390/vaccines9040382 |
_version_ | 1783683320644632576 |
---|---|
author | Rzymski, Piotr Zeyland, Joanna Poniedziałek, Barbara Małecka, Ilona Wysocki, Jacek |
author_facet | Rzymski, Piotr Zeyland, Joanna Poniedziałek, Barbara Małecka, Ilona Wysocki, Jacek |
author_sort | Rzymski, Piotr |
collection | PubMed |
description | Vaccine hesitancy is a major threat to the success of COVID-19 vaccination programs. The present cross-sectional online survey of adult Poles (n = 1020) expressing a willingness to receive the COVID-19 vaccine was conducted between February and March 2021 and aimed to assess (i) the general trust in different types of vaccines, (ii) the level of acceptance of the COVID-19 vaccines already in use in Poland (BNT162b2 by BioNTech/Pfizer, mRNA-1273 by Moderna and AZD1222 by Oxford/AstraZeneca) as well as eight vaccines approved outside European Union (EU) or in advanced stages of clinical trials, (iii) level of fear of vaccination against COVID-19, and (iv) main sources of information on COVID-19 vaccination. Among all major vaccine technology, the highest level of trust was observed for the mRNA platform, with a considerable number of surveyed (>20%) not aware of the existence of vaccines produced using the traditional approach (inactivated and live attenuated vaccines). The age of participants was the main factor differentiating the level of trust in a particular vaccine type. Both BNT162b and mRNA-1273 received a high level of acceptance, contrary to AZD1222. From eight vaccines unauthorized in the EU at the moment of study, the CVnCoV (mRNA; CureVac) was met with the highest level of trust, followed by Ad26.COV2.S (vector; Janssen/Johnson&Johnson) and NVX-CoV2373 (protein; Novavax). Sputnik V (vector; Gamaleya Research Institute) was decidedly the least trusted vaccine. The median level of fear (measured by the 10-point Likert-type scale) in the studied group was 4.0, mostly related to the risk of serious allergic reactions, other severe adverse events and unknown long-term effects of vaccination. Female, individuals with a lower level of education and those not seeking any information on the COVID-19 vaccines revealed a higher fear of vaccination. Experts’ materials were the major source of information on COVID-19 vaccines in the studied group. The study shows the level of trust in COVID-19 vaccines can vary much across the producers while the mRNA vaccines are received with a high level of acceptance. It also emphasizes the need for effective and continuous science communication when fighting the pandemic as it may be an ideal time to increase the general awareness of vaccines. |
format | Online Article Text |
id | pubmed-8069794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80697942021-04-26 The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland Rzymski, Piotr Zeyland, Joanna Poniedziałek, Barbara Małecka, Ilona Wysocki, Jacek Vaccines (Basel) Article Vaccine hesitancy is a major threat to the success of COVID-19 vaccination programs. The present cross-sectional online survey of adult Poles (n = 1020) expressing a willingness to receive the COVID-19 vaccine was conducted between February and March 2021 and aimed to assess (i) the general trust in different types of vaccines, (ii) the level of acceptance of the COVID-19 vaccines already in use in Poland (BNT162b2 by BioNTech/Pfizer, mRNA-1273 by Moderna and AZD1222 by Oxford/AstraZeneca) as well as eight vaccines approved outside European Union (EU) or in advanced stages of clinical trials, (iii) level of fear of vaccination against COVID-19, and (iv) main sources of information on COVID-19 vaccination. Among all major vaccine technology, the highest level of trust was observed for the mRNA platform, with a considerable number of surveyed (>20%) not aware of the existence of vaccines produced using the traditional approach (inactivated and live attenuated vaccines). The age of participants was the main factor differentiating the level of trust in a particular vaccine type. Both BNT162b and mRNA-1273 received a high level of acceptance, contrary to AZD1222. From eight vaccines unauthorized in the EU at the moment of study, the CVnCoV (mRNA; CureVac) was met with the highest level of trust, followed by Ad26.COV2.S (vector; Janssen/Johnson&Johnson) and NVX-CoV2373 (protein; Novavax). Sputnik V (vector; Gamaleya Research Institute) was decidedly the least trusted vaccine. The median level of fear (measured by the 10-point Likert-type scale) in the studied group was 4.0, mostly related to the risk of serious allergic reactions, other severe adverse events and unknown long-term effects of vaccination. Female, individuals with a lower level of education and those not seeking any information on the COVID-19 vaccines revealed a higher fear of vaccination. Experts’ materials were the major source of information on COVID-19 vaccines in the studied group. The study shows the level of trust in COVID-19 vaccines can vary much across the producers while the mRNA vaccines are received with a high level of acceptance. It also emphasizes the need for effective and continuous science communication when fighting the pandemic as it may be an ideal time to increase the general awareness of vaccines. MDPI 2021-04-14 /pmc/articles/PMC8069794/ /pubmed/33919672 http://dx.doi.org/10.3390/vaccines9040382 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rzymski, Piotr Zeyland, Joanna Poniedziałek, Barbara Małecka, Ilona Wysocki, Jacek The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland |
title | The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland |
title_full | The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland |
title_fullStr | The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland |
title_full_unstemmed | The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland |
title_short | The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland |
title_sort | perception and attitudes toward covid-19 vaccines: a cross-sectional study in poland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069794/ https://www.ncbi.nlm.nih.gov/pubmed/33919672 http://dx.doi.org/10.3390/vaccines9040382 |
work_keys_str_mv | AT rzymskipiotr theperceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT zeylandjoanna theperceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT poniedziałekbarbara theperceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT małeckailona theperceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT wysockijacek theperceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT rzymskipiotr perceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT zeylandjoanna perceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT poniedziałekbarbara perceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT małeckailona perceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland AT wysockijacek perceptionandattitudestowardcovid19vaccinesacrosssectionalstudyinpoland |